Oral Drug Highly Active in Rare Blood Cancers With FGFR1 Rearrangements
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(Medage today) – Most patients with myeloid / lymphoid neoplasms with FGFR1 rearrangements receiving pemigatinib (pemazyre) have experienced full responses in phase II Fight -203 test. Among 45 patients analyzed for efficiency, the whole whole …
